Increasing breast cancer chemoprevention in the primary care setting

描述（由申请人提供）：乳腺癌是美国女性中最常见的恶性肿瘤，这种疾病的一级预防是一个重大的公共卫生问题。尽管几项随机对照试验表明高危女性乳腺癌发病率降低了50-65%，但使用抗雌激素（如他莫昔芬、雷洛昔芬和依西美坦）的乳腺癌化学预防尚未得到充分利用。许多妇女可能不知道自己的高风险状态，由于我们无法充分筛选他们在初级保健设置。其他低吸收的原因包括咨询时间不足，对降低风险策略的知识不足，以及对副作用的担忧。与非西班牙裔白人相比，少数种族/族裔妇女不太可能寻求预防措施，导致这些人群的临床结局较差。我们假设，将以患者为中心的决策辅助与以医生为中心的决策支持工具结合到临床工作流程中，将提高乳腺癌风险感知的准确性，促进专业风险咨询的转诊，并增加化学预防的使用。 在我们的乳腺诊所中，高危女性的化学预防摄取率为37%，而其他高危人群的摄取率不到5%。我们的目标是通过为在初级保健环境中筛查的更广泛的种族/民族多样的妇女提供专门的风险咨询，扩大我们在乳腺诊所的成功。我们将使用一种新的乳腺癌风险导航（BNAV）工具，该工具将盖尔乳腺癌风险模型纳入电子健康记录。为了解决与患者相关的化学预防障碍，我们的研究小组开发了一种决策辅助工具RealRisks的初始原型，允许参与者通过活动体验风险。我们建议进行以下目标：1a）应用以用户为中心的设计来评估和改进乳腺癌化学预防的RealRisks; 1b）在我们的乳腺诊所和高风险登记处确定的50名高风险女性中评估RealRisks对乳腺癌风险感知准确性的影响; 2a）为初级保健提供者设计和评估BNAV，以帮助识别符合化学预防条件的高危妇女; 2b）比较在初级保健诊所筛选的50名高危妇女随机接受BNAV与不接受BNAV的乳腺诊所转诊率; 3）采用RealRisks和BNAV的2x2析因设计进行随机对照试验，无论是单独使用还是联合使用，与在初级保健环境中确定的400名高危妇女的常规护理相比。主要终点是6个月时的化学预防摄取。其次，我们将评估风险感知的准确性，乳腺诊所的转诊率，以及各种患者和医生报告的结果。 该提案旨在克服初级保健环境中化学预防吸收的重要障碍。鉴于抗雌激素药物在高危人群中的一级预防中已被证明有效，提高乳腺癌化学预防的使用率可能会显着减少这种疾病的公共卫生负担。

DESCRIPTION (provided by applicant): Breast cancer is the most common malignancy among women in the U.S. and the primary prevention of this disease is a major public health issue. Breast cancer chemoprevention with antiestrogens, such as tamoxifen, raloxifene, and exemestane, is underutilized, despite several randomized controlled trials demonstrating a 50-65% decrease in breast cancer incidence among high-risk women. Many women may be unaware of their high-risk status due to our inability to adequately screen them in the primary care setting. Other reasons for low uptake include inadequate time for counseling, insufficient knowledge about risk- reducing strategies, and concerns about side effects. Women from racial/ethnic minorities are less likely to seek preventive measures, contributing to poorer clinicl outcomes in these populations compared to non- Hispanic whites. We hypothesize that combining a patient-centered decision aid with a physician-centered decision support tool integrated into clinic workflow will improve accuracy of breast cancer risk perception, facilitate referrals for specialized risk counseling, and increase chemoprevention uptake. In our breast clinic, the chemoprevention uptake rate among high-risk women is 37%, compared to less than 5% reported for other high-risk populations. Our goal is to expand our success in the breast clinic by offering specialized risk counseling to a broader population of racially/ethnically divere women screened in the primary care setting. We will use a novel breast cancer risk navigation (BNAV) tool, which incorporates the Gail breast cancer risk model into the electronic health record. To address patient-related barriers to chemoprevention, our research group developed an initial prototype of a decision aid, RealRisks, that allows participants to experience risk through an activity. We propose to conduct the following aims: 1a) To apply a user-centered design to evaluate and refine RealRisks for breast cancer chemoprevention; 1b) To evaluate the effects of RealRisks on accuracy of breast cancer risk perception among 50 high-risk women identified at our breast clinic and high-risk registries; 2a) To design and evaluate BNAV for primary care providers to facilitate the identification of high-risk women eligible for chemoprevention; 2b) To compare referral rates to the breast clinic among 50 high-risk women screened in primary care clinics randomized to BNAV vs. no BNAV; 3) To conduct a randomized controlled trial with a 2x2 factorial design of RealRisks and BNAV, either alone or in combination, compared to usual care in 400 high-risk women identified in the primary care setting. The primary endpoint is chemoprevention uptake at 6 months. Secondarily, we will assess accuracy of risk perception, referral rates to the breast clinic, and various patient- and physician-reported outcomes. This proposal seeks to overcome important barriers to chemoprevention uptake in the primary care setting. Given the proven efficacy of antiestrogens for primary prevention in high-risk populations, higher uptake of breast cancer chemoprevention may significantly reduce the public health burden of this disease.